Curis | CRIS - Ebitda


Curis reported $-12.3M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Amgen USD 5.8B 1.25B Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Bayer EUR 1.62B 529M Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
CSL USD 3.13B 1.17B Dec/2025
Curis USD -12.3M 231K Sep/2023
Eli Lilly USD 9.46B 3.54B Sep/2026
Exelixis USD 275.36M 19.96M Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Novartis USD 8.62B 2.14B Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Takeda JPY 369.75B 5.29B Sep/2026
TG Therapeutics USD 26.9M 1.21M Jun/2026